Dr. Zeng received his M.D. from Xiangya Medical School of Central South University and practiced in Neuropsychiatric specialty in China. After subsequently earning a Ph.D. in Molecular Pathology at Otago Univerisy, New Zealand, he accepted a postdoctoral fellowship at Massachusetts General Hospital and discovered SLC19A3 gene defective in biotin-responsive basal ganglia disease under mentorship of Dr. James Gusella. Dr. Zeng completed the Clinical Molecular Genetics Fellowship Program at Harvard Medical School and served as Co-Director of Clinical Molecular Diagnostic Laboratory at City of Hope National Cancer Center and Associate Medical Director at MEDomics prior to joining Ambry in 2011. Dr. Zeng is certified in clinical molecular genetics by the American Board of Medical Genetics. Additionaly, Dr. Zeng holds lab director licenses in California and New York and has earned a Certificate of Qualification in both molecular genetics and molecular oncology.